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Abstract 
Several autoimmune diseases including multiple sclerosis (MS) cause increased transcription 
of endogenous retroviruses (HERVs) normally repressed by heterochromatin. In parallel, 
HERV‐derived sequences were reported to drive gene expression. Here, we have examined a 
possible link between promoter and enhancer divergent transcription and the production of 
HERV transcripts. We find that HERV‐derived sequences are in general counter‐selected at 
regulatory regions, a counter‐selection that is strongest in brain tissues while very moderate in 
stem cells. By exposing T cells to the pesticide dieldrin, we further found that a series of 
HERV‐driven enhancers otherwise active only at stem cell stages can be reactivated by stress. 
This in part relies on peptidylarginine deiminase activity, possibly participating in the 
reawakening of silenced enhancers. Likewise, usage of HERV‐driven enhancers was 
increased in myelin‐reactive T cells from patients with MS, correlating with activation of 
nearby genes at several sites. Altogether, we propose that HERV‐driven enhancers constitute 
a reservoir of auxiliary enhancers transiently induced by stress while chronically active in 
diseases like MS. 
 
 
 
 
 
 
 
Synopsis 
 
 
 
 
 
 
Human endogenous retroviruses (HERVs) derived from ancient exogenous viruses can act as 
cis‐enhancers. This study shows that increased disease‐related gene expression is in part due 
to a chronic increase of HERV cis‐enhancer activity in the context of autoimmune diseases. 
• Enhancers driven by HERVs are enriched in the neighborhood of immune genes. 
• HERV‐driven enhancers are mostly active in embryonic cells but silenced in mature 
adult tissues. 
• Extensive stress causes transient reactivation of HERV transcription. 
• In multiple sclerosis, some HERV‐driven regulatory regions become chronically 
active. 
 
 
Introduction 
Several autoimmune diseases including multiple sclerosis (MS), type 1 diabetes mellitus, and 
rheumatoid arthritis are associated with increased transcription of sequences originating from 
ancient retroviral infections of the germ line. The possible role of these human endogenous 
retroviruses (HERVs) in the onset of autoimmune diseases has been extensively investigated, 
mostly with a focus on their protein products, that trigger immune reactions and occasionally 
assemble into virus‐like particles (Christensen, 2016; Nexø et al, 2016). In contrast, the 
regulatory mechanisms at the root of the increased transcription of HERV‐derived sequences 
in the patients remain essentially unexplored. This is an important issue as the understanding 
of transcriptional events associated with autoimmune diseases may help unraveling the 
mechanisms leading to their onset.  
Transposable elements are maintained under strict transcriptional control via a combination of 
DNA methylation, histone H3 lysine 9 methylation, and binding of KRAB domain‐containing 
zinc‐finger proteins (Karimi et al, 2011; Imbeault et al, 2017). It has been suggested that the 
function of the silencing is to restrain the mobility of the repeated elements and prevent them 
from damaging the genome. While mobility may be an issue for other transposable elements 
like LINES that maintain transposition capacity, there is currently no evidence for new 
somatic or germ line insertions of  HERVs in humans, and nearly all have lost coding 
potential (Bannert & Kurth, 2006; Magiorkinis et al, 2015). Another possibility is that HERV 
sequences require silencing because of their regulatory potential. Indeed, HERVs are an 
important source of cis‐regulatory elements initially necessary for the viral cycle, and several 
studies have established exaptation of HERV‐derived sequences for the transcriptional 
regulation of host genes, mostly involved in stemness and development, but also in immunity 
and antiviral defense (Sundaram et al, 2014; Wang et al, 2014; Chuong et al, 2016; Hackett 
et al, 2017; Hummel et al, 2017; Imbeault et al, 2017). As an argument in favor of a 
regulatory role of HERVs, post‐translational histone modifications characteristic of promoters 
and enhancers have been detected on retroviral sequences (Chuong et al, 2013; Xie et al, 
2013). These histone modifications include the promoter‐specific histone H3 lysine 4 tri‐
methylation and the enhancer‐enriched histone H3 lysine 4 monomethylation and lysine 27 
acetylation (Calo & Wysocka, 2013). In parallel, HERVs have been reported to contribute 
significantly more than expected by chance to DNase I accessible regions, characteristic of 
transcribed DNA sequences (Jacques et al, 2013).  
The implication of HERV‐derived sequences in transcriptional regulation justifies their tight 
regulation, but it may also provide an explanation for their transcription. Indeed, promoters 
and enhancers are sites of (mostly) bidirectional transcription and the abundance of product of 
this transcription (uaRNAs for promoters and eRNAs for enhancers) reflects the activity of 
the regulatory sequences (Kim et al, 2010; Melgar et al, 2011; Hah et al, 2013). Thus, 
promoter or enhancer activity represents an opportunity for HERV‐derived sequences to be 
transcribed, whether they are located at the site of transcription initiation or in its vicinity, and 
this could be the basis for HERV transcripts detected in autoimmune diseases.  
To investigate this possibility, we have here examined the position of HERV‐derived 
sequences relative to enhancers and promoters. For this, we have taken advantage of the 
systematic mapping of functional domains by the NIH Roadmap Epigenomics Mapping and 
the Fantom5 consortia, respectively, relying on combinations of histone modifications 
detected by chromatin immunoprecipitation assays and on Cap Analysis of Gene Expression 
(CAGE), defining sites of transcription initiation. The approach showed that the bulk of 
HERV‐containing sequences are counter‐selected inside promoters and enhancers and even 
more so at the borders of these regulatory regions. Yet, it also confirmed that a subset of 
HERV sequences function as cis‐regulatory elements active mostly in embryonic stem cells 
and frequently located in the neighborhood of genes involved in innate immune defense. To 
investigate whether transcriptional activation of such HERV‐driven cis‐regulatory elements 
could be a source of disease‐related HERV transcripts, we identified a small molecule able to 
induce transcription of several MS‐associated HERVs. This allowed us to show that 
production of disease‐related HERV transcripts accompanies an acute stress‐induced 
transcriptional response that involves awakening of cis‐regulatory elements atypical for 
mature T cells and enriched in HERV‐driven enhancers. Finally, examination of 
transcriptomic data from patients with MS revealed a chronic disease‐associated increase in 
the usage of HERV‐driven enhancers, resulting in the production of HERV transcripts, and 
correlating with transcriptional activation of nearby genes.  
Results 
HERV‐driven enhancers and promoters are rare and tissue‐specific 
To reach an overview of the participation of HERV‐derived sequences in transcription 
initiation throughout human tissues, we extracted all regions annotated as active promoters or 
enhancers in the 127 tissues mapped by the NIH Roadmap Epigenomics Mapping Consortium 
(Roadmap Epigenomics Consortium et al, 2015). These regions will be referred to as PEs for 
“Promoter or Enhancer” regions. To estimate the similarity between each of the 127 sets of 
PEs and regions annotated “LTR” in RepeatMasker, we used the Jaccard index defined as the 
size of the intersection divided by the size of the union of the sample sets. As the total number 
of PEs varies among the tissues, we also calculated the Jaccard index between the PEs from 
each tissue and randomly selected non‐LTR regions (average of thousand iterations). The 
score shown for each tissue is the Jaccard index (PEs vs. LTRs) divided by the Jaccard index 
(PEs vs. random). The approach showed that in all tissues, the overlap between PEs and 
HERVs is smaller than that expected by chance (all ratios are below 1, Fig 1A, full list 
Appendix Fig S1A). It also showed that overlap of HERV sequences with PEs varied 
extensively from one tissue to the other, with several pluripotent stem and cancer cell lines 
harboring HERV sequences inside their PEs approximately fourfold more frequently than 
tissues at the bottom of the list. These last‐mentioned tissues notably included pancreatic 
islets, several brain tissues, and tissues from the gastrointestinal tract. To further explore the 
tissue specificity of HERV‐driven PEs, we also compared LTRs to either ubiquitous or tissue‐
specific PEs. Likewise, we compared LTRs to either evolutionary conserved or human‐
specific liver cis‐regulatory elements (Appendix Fig S1B). In these tests, tissue‐specific and 
human‐specific elements reached the best similarity scores with LTRs, in agreement with 
earlier observations (Trizzino et al, 2017, 2018).  
We next examined the position of HERV sequences relative to PEs. In all tissues, the PEs 
were located at the bottom of a HERV‐depleted valley (Fig 1B). This indicates that the 
neighborhood of PEs is depleted of HERV sequences, possibly to avoid their serendipitous 
transcription (schematic in Fig 1C). In all tissues except pancreatic islets and fetal female 
brain, we also noted an upturn of variable size within the core of the PEs. In a vast majority of 
tissues, this upturn or “HERV‐butte” remained below the basal level (considered 10 kb away 
from the PE—see, e.g., HUES6 and pancreatic islets). However, in a series of embryonic stem 
and iPS cells and in the K562 leukemia cell line, the HERV‐butte reached at or above the 
baseline, indicative of extensive usage of HERV sequences in the PEs of these cells (Fig 1B 
and Appendix Fig S1C–F). We further tested whether the evolutionary age of the LTRs would 
affect their position relative to PEs (Appendix Fig S1G–I). Examinations of the profiles 
suggested that the ERV1 clade (approximately 170,000 copies) is better tolerated in the 
neighborhood of PEs than is the older ERVL clade (approximately 500,000 copies), in 
agreement with an earlier study showing that ERV1 is the most abundant LTR within cis‐
regulatory elements (Trizzino et al, 2017). The younger ERVKs were too few in number for 
the profiles to be meaningful (approximately 10,000 copies).  
The presence of a HERV‐butte inside the boundaries of the PEs in most tissues prompted us 
to specifically examine HERVs likely to be the functional core of promoters or enhancers. To 
that end, we listed RepeatMasker “LTRs” overlapping with a PE in at least one of the 127 
tissues while also matching a Fantom5 Cap Analysis of Gene Expression (CAGE) peak 
(example in Fig 1D and Appendix Fig S1M). These CAGE peaks define sites of 
transcriptional initiation active in at least one of the 975 CAGE libraries examined by the 
Fantom5 consortium (DGT, 2014). This approach selected approximately 1% of all HERV 
sequences (6684 “CAGE‐LTRs” out of 708210 regions annotated “LTR”). Interestingly, 
CAGE‐LTRs had highest similarity (Jaccard index) with PEs from several hematopoietic 
tissues, while brain tissues segregated clearly at the bottom of the list (Appendix Fig S1N). 
We then identified genes located within 100 kb of the CAGE‐LTRs using GREAT (McLean 
et al, 2010). GO term analysis of these genes showed a clear enrichment in genes involved in 
cytokine and inflammatory response (Fig 1E).  
 Figure 1.Genome‐wide localization of HERVs relative to promoters and enhancers  
A. Comparison of regions annotated “LTR” in RepeatMasker with the regions annotated TssA, TssAFlnk, Enh, EnhG, TssBiv, or 
EnhBiv in the 15 core marks model of the Epigenomic Roadmap consortium (referred to as PEs for Promoters and Enhancers). 
For each tissue, the Jaccard index comparing PEs to LTRs is divided by the average Jaccard index (1,000 iterations) obtained 
when comparing PEs to randomly selected genomic locations (of the same sizes as the LTRs). Only the 10 tissues with the 
highest and the lowest score are shown. Full list in Appendix Fig S1A.  
B. Profile reporting the position of regions annotated “LTR” in RepeatMasker relative to PEs from the indicated tissues. Red and 
blue horizontal lines materialize the level of LTR density expected in a random sequence from pancreatic islets and human 
embryonic stem cell line HUES6, respectively. 
C. A graphic interpretation of the positioning of PEs at the bottom of LTR valleys in panel (A). 
D. Example of a region annotated “LTR” in RepeatMasker and overlapping with a PE and with a CAGE peak from the FANTOM5 
consortium data, indicative of a site of transcription initiation. 
E. Biological process GO terms associated with genes located 100 kb or less from a region annotated “LTR” in RepeatMasker and 
overlapping with a PE and with a CAGE peak. 
 
As above, we next stratified the LTRs according to their evolutionary age. The ERV1 clade 
showed the highest similarity with CAGE peaks (Appendix Fig S1J) with approximately 2% 
of the ERV1 copies hosting a CAGE peak; the younger ERVKs showed the lowest similarity. 
GO term analysis of genes located within 100 kb of CAGE‐containing ERV1s essentially 
recapitulated that reached when considering all CAGE‐LTRs (Appendix Fig S1L). GO term 
analysis of genes located within 100 kb of CAGE‐containing ERVLs also designated 
pathways related to innate immunity, yet with a focus on the interferon gamma response 
(Appendix Fig S1K). In contrast, ERVKs did not appear to have specialized in any specific 
pathway. We note however here that, due to the difficulty of their single‐locus mapping, the 
impact of these relatively young HERVs on transcriptional regulation may be underestimated.  
Altogether, we concluded from this analysis that (i) most HERV sequences are located away 
from sites of transcriptional initiation and are therefore less likely to be transcribed 
accidentally upon activation of a neighboring promoter or enhancer, (ii) the usage of HERVs 
as cis‐regulatory elements varies extensively from one tissue to the other, being highest in 
stem and cancer cells and lowest in brain tissues, (iii) cis‐regulatory elements borne by HERV 
sequences, while associated with multiple regulatory pathways, play a distinct role in the 
regulation of immune genes, in line with earlier observations on the role of HERV sequences 
in cellular defense (Chuong et al, 2016; Grandi & Tramontano, 2018).  
 
Dieldrin as a tool to induce transcription of disease‐related HERVs 
To challenge the bioinformatic analysis described above, we searched for a reliable tool to 
activate HERVs in a tissue culture cell line. In an initial approach, we chose to monitor some 
of the HERVs of the H, K, and W clades frequently described as activated in patients with 
autoimmune diseases (Appendix Fig S2A). Searching the literature for compounds potentially 
interfering with heterochromatin‐mediated repression brought us to test dieldrin, an 
organochlorine pesticide described as an inducer of histone acetylation in dopaminergic 
neuronal N27 cells (Song et al, 2010). In our assays, we examined the effect of dieldrin on 
HERV transcription in the Jurkat CD4+ T‐cell line in which we had previously observed 
inducible HERV activity (Sharma et al, 2012). The sequences of the primers we used to detect 
HERV transcription were obtained from the literature, yet they all detected more than one 
locus in both Jurkat and haploid HAP1 cells as determined by digital droplet PCR 
(Appendix Fig S2B). Titration experiments showed that Jurkat cells tolerated dieldrin at 
concentrations up to 100 μM for 1 h with no significant cell death (< 2%—Appendix Fig 
S2C). Exposure to that dosage resulted in a very transient increase in transcription for 6 of the 
7 tested HERVs (twofold to fourfold) peaking at 30 min, while being undetectable at 60 min 
(Fig 2A). In comparison, activation of the Jurkat T cells with 100 μM of the phorbol ester 
PMA did not induce HERV expression (Fig 2B). The concentration of PMA was here 
intentionally higher than that usually used (40 nM) to ascertain that the absence of HERV 
stimulation was not a consequence of insufficient dosage. Cell responsiveness to PMA was 
verified by monitoring activation of two cytokine genes TNFα and IL8 (Appendix Fig S2D). 
As a negative control, we monitored TGFβ, a gene induced neither by PMA nor dieldrin 
(Fig 2A).  
  
Figure 2. Dieldrin is a strong T‐cell activator causing transcription of several HERVs  
A–E. Jurkat T cells were treated with either DMSO (vehicle) or with 100 μM of either dieldrin or PMA for the indicated times. 
Abundance of mRNA for the indicated genes or HERVs was assessed by RT–qPCR. Data shown are means ± SEM from four 
independent experiments. Significance (P‐value) was estimated using the two‐sided Student's t‐test appropriate for small sample 
numbers. ***P‐value < 0.001. 
F. Jurkat cells were exposed to either DMSO, PMA in DMSO, or dieldrin in DMSO for 30 min in triplicates. RNA‐seq was then 
performed on cDNA libraries prepared with poly(A) selection: principal component analysis on the 485 genes the most affected by 
DMSO, PMA, or dieldrin. 
G. Venn diagrams reporting genes up‐ or down‐regulated by dieldrin or PMA as compared to DMSO. 
H, I. Gene ontology analysis on genes up‐ and down‐regulated by either dieldrin or PMA as estimated from RNA‐seq data. 
 
To gain insight into the global effect of dieldrin on gene expression, we used next‐generation 
sequencing of a poly(A)‐enriched random‐primed cDNA library after a 30‐min exposure. The 
transcriptome was compared to that of untreated cells or cells activated with PMA. Dieldrin 
caused exceptionally strong activation of multiple markers of T‐cell activation, including 
CD69, SERPINE1, and the immediate early genes JUN, FOS, FOSB, EGR2/3/4, and 
NR4A1/2/3 (Table EV1, Fig 2C–E, and MA plots Appendix Fig S2E–F). Yet, principal 
component analysis positioned the effect of dieldrin away from that of PMA (Fig 2F). In 
particular, the effect of dieldrin was more extensive than that of PMA with 246 genes 
significantly upregulated by dieldrin, while only 93 genes were upregulated by PMA (false 
discovery rate, FDR < 0.05). KEGG pathway analysis further suggested that dieldrin was a 
particularly efficient activator of the MAPK pathway (Fig 2H and I). Finally, dieldrin caused 
moderate (less than twofold) but significant (FDR < 0.05) transcriptional repression of a large 
set of genes (197 genes—Fig 2G and Table EV1) along with moderate (less than twofold) 
activation of heat‐shock proteins HSPA6, HSPA1A/B, and HSPH1. This was suggestive of an 
early phase of a heat‐shock response antagonizing protein misfolding in the cytosol (Mahat 
et al, 2016). Dieldrin did not seem to induce other types of stress as confirmed by RT–qPCR 
analysis of a series of gene markers for environmental, oxidative, osmotic, cytotoxic, hypoxic, 
endoplasmic reticulum, or metal stress (Appendix Fig S2G and H).  
 
Atypical T‐cell enhancers are enriched in HERVs 
We next questioned whether the transcription of HERV‐derived sequences induced by 
dieldrin could be an indicator of increased usage of HERV‐driven enhancers. HERV 
transcription induced by dieldrin was poorly detected in the poly(A)‐enriched data (see 
example of an ERV1 downstream of the RIMS2 gene, Fig 3A, top lanes). We therefore 
repeated the RNA‐seq on one set of samples using cDNA libraries constructed from ribo‐
depleted total RNA. This protocol allowed us to detect and quantify non‐coding RNAs, 
including those resulting from transcription of HERV‐derived sequences (see example 
Fig 3A, bottom). The inadequacy of the poly(A)‐enriched data for the detection of HERV 
transcription was confirmed by examining a series of 4686 HERVs transcribed twofold or 
more in the ribo‐depleted data. On average, the read count at these sequences was not affected 
by dieldrin in the data from the poly(A)‐enriched transcripts in any of the replicates (Fig 3B). 
These observations suggested that HERV transcripts in their majority are not stably 
polyadenylated and therefore unlikely to be messenger RNAs (mRNAs).  
We next mapped putative promoters and enhancers based on detection of sites of divergent 
transcription in both DMSO‐ (solvent) and dieldrin‐treated cells. To increase robustness, we 
retained only positions previously annotated as sites of transcription initiation in at least one 
of the 975 CAGE libraries of the Fantom5 consortium. Examination of the distribution of 
RepeatMasker LTRs relative to the sites of divergent transcription revealed that dieldrin did 
not allow overcoming the counter‐selection of HERV sequences in PEs, yet it increased the 
usage of HERV‐containing PEs by approximately 25% (Fig 3C, compare blue and green 
lines).  
We next concentrated on sites of divergent transcription activated twofold or more in the 
presence of dieldrin (referred to as APEs for activated promoters and enhancers—Table EV2). 
 
 Figure 3.Dieldrin causes transcription of HERV‐containing PEs atypical for activated T cells  
Jurkat cells were exposed to either DMSO or dieldrin in DMSO for 30 min. RNA‐seq was then performed on cDNA libraries prepared after 
depletion of ribosomal RNAs.  
A. Screen captures from IGV showing an example of a HERV becoming a site of divergent transcription upon exposure of the Jurkat 
cells to dieldrin. Top tracks show coverage from sequencing of poly(A)‐enriched libraries for comparison. All coverage tracks are 
at the same scale, and all the sequencing result files are of comparable size. Blue and red reads (rds) are in opposite orientation. 
CAGE peaks use the same color code. 
B. Reads mapping inside a series of 4,686 HERVs located away (30 kb) from protein‐coding genes were quantified both in the 
poly(A)‐enriched and the ribo‐depleted data. Read counts from each replicate were then summed and plotted. 
C. Distribution of regions annotated “LTR” in RepeatMasker relative to sites of divergent transcription in Jurkat cells treated with 
either DMSO or dieldrin in DMSO. 
D. Schematic showing that only a fraction of the APEs (sites of divergent transcription activated twofold or more by dieldrin) match 
promoters and enhancers annotated as active in T cells (APETs). The remaining APEs are designated APEDs (specific to the 
dieldrin treatment). 
E. Comparison of regions annotated “LTR” in RepeatMasker with the APEs, APETs, and APEDs. The graph provides the ratio 
between the Jaccard index of the indicated category over the average of Jaccard indexes calculated for 1,000 series of randomly 
selected PEs. 
F. , G. Comparison of either APEs or APEDs as indicated with the regions annotated TssA, TssAFlnk, Enh, EnhG, TssBiv, or 
EnhBiv in the 15 core marks model of the Epigenomic Roadmap consortium as in Fig 1A. 
H. Region upstream of IL2 as a screen capture from the genome browser of the Epigenomic Roadmap consortium. Promoters and 
enhancers are annotated in red and yellow, respectively. Green indicates transcription. Insert is a detail from Appendix Fig S3A 
showing the site of divergent transcription induced by dieldrin. 
I. Jurkat T cells were treated with either DMSO (vehicle) or 100 μM dieldrin for the indicated times. Abundance of IL2 mRNA was 
assessed by RT–qPCR. Data shown are means ± SEM from four independent experiments. Significance (P‐value) was estimated 
using the two‐sided Student's t‐test appropriate for small sample numbers. ***P‐value < 0.001. 
J. Screen captures from IGV showing increased divergent transcription inside a HERV sequence upon exposure of the Jurkat cells 
to dieldrin in the intergenic region between MUC21 and MUC22. Color code as in (A). 
The Jaccard similarity index between APEs and RepeatMasker LTRs was fivefold higher than 
expected for randomly selected sites of divergent transcription, indicating a further 
enrichment in HERV sequences among sites of divergent transcription strongly activated by 
dieldrin (Fig 3E, APE). We next separated APEs annotated as active in T‐cell epigenomes 
(APETs) from those atypical for T cells and more likely to be dieldrin‐specific (termed APED 
for dieldrin‐specific, Fig 3D). This latter group was threefold richer in HERV sequences than 
the APETs as shown by the Jaccard similarity index (Fig 3E, compare APET and APED). 
Furthermore, comparing APEs and APEDs with the PEs from the 127 epigenomes (Jaccard 
index) showed that filtering away T‐cell PEs from the APEs, generated a list of regulatory 
sites sharing similarity with PEs from the cancer cell line Dnd41, from fetal thymus, and from 
several hematopoietic stem cell lines (Fig 3F and G). This suggested that APEDs included 
regulatory sequences active in less differentiated hematopoietic cells.  
Taken together, this analysis suggested that dieldrin causes activation of regulatory sequences 
required for T‐cell activation, but also of more atypical regulatory regions enriched in HERV 
sequences. To identify examples of such atypical regulatory regions, we examined 
individually some of the sites of divergent transcription overlapping with HERV sequences 
and activated by dieldrin. We particularly noted the presence of a site located upstream of 
IL2, annotated as an active enhancer in stem cells and in the K562 leukemia‐derived cell line, 
but not in primary hematopoietic cells (Fig 3H and Appendix Fig S3A). At the time point 
examined by RNA‐seq (30 min of exposure to dieldrin), the IL2 gene is still in a phase of 
progressive activation (Fig 3I). Remarkably, at this time, the HERV‐driven enhancer had a 
transcriptional activity stronger than that observed at the two enhancers annotated as active in 
T cells (arrows, Appendix Fig S3A). This observation suggested that activation of the IL2 
gene by dieldrin largely relied on the activity of a HERV‐driven enhancer atypical for T cells. 
The atypical nature of enhancers overlapping with HERV sequences was also well illustrated 
by a site located upstream of the gene encoding the Fc receptor‐like protein 4 (FCRL4) on 
chromosome 1, annotated as an enhancer in T cells from cord blood and in the Dnd41 T‐cell 
leukemia cell line, while annotated as Polycomb‐repressed, heterochromatinized, or quiescent 
in all other T‐cell epigenomes (Appendix Fig S3B). Finally, we noted two unannotated 
HERV‐based enhancers in the neighborhood of mucin genes MUC21 and MUC22, further 
suggesting that HERV sequences provide alternative enhancers for genes involved in cellular 
defense (Fig 3J and Appendix Fig S3C).  
Atypical activation of multiple pathways by dieldrin is required for HERV transcription 
To gain a better insight into how dieldrin may drive Jurkat cells into using atypical enhancers, 
we next investigated the signal transduction pathways stimulated by this molecule in 
comparison with PMA. A human phospho‐kinase array showed that both dieldrin and PMA 
treatments activated the MAP kinase pathway as demonstrated by the phosphorylation of the 
TXY motif in ERK1/2 proteins and of the SRF kinases RSK1/2/3 (Fig 4A and B, and 
Appendix Fig S4A and B). In this context, we also examined phosphorylation of PKC, the 
primary target of PMA. Surprisingly, dieldrin, unlike PMA, did not cause any detectable 
change in PKC phosphorylation when examined by Western blot with a pan phospho‐PKC 
antibody (Fig 4C phospho‐PKC, compare lanes 2 and 6), suggesting that dieldrin activates the 
MAP kinase pathway independently of the PKC pathway.  
Jurkat cells fail to express PTEN and SHIP lipid phosphatases and therefore have elevated 
basal activity of the PI3K pathway. This activity accounted for the high levels of AKT S473 
phosphorylation detected on the phospho‐kinase arrays (Appendix Fig S4A, arrow). 
Nevertheless, both PMA and dieldrin caused increased TOR phosphorylation at S2448, 
suggestive of a further activation of the pathway (Fig 4B). However, only PMA induces 
detectable phosphorylation of REL A, a downstream target of the PI3K pathway (Fig 4C REL 
A, compare lanes 2 and 6), again suggesting an atypical effect of dieldrin on this kinase 
cascade.  
Finally, we examined pathways activated by increased calcium concentrations. On the kinase 
array, both dieldrin and PMA caused phosphorylation of CREB at S133, a modification 
catalyzed either by PKA or by CamK in the presence of Ca2+. In contrast, dieldrin, but not 
PMA, caused NFATc2 de‐phosphorylation, an indicator of the activation of the 
calcium/calmodulin pathway (Fig 4C NFAT‐1, compare lanes 2 and 6).  
Together, these observations documented a simultaneous activation by dieldrin of the MAPK, 
the PI3K, and the calcium/calmodulin pathways, possibly via atypical routes. To investigate 
the importance of these pathways in the activation of HERV transcription, we tested several 
small‐molecule inhibitors. For these experiments, we monitored transcription using the 
HERVH env62 primer set. Indeed, sequencing of the resulting PCR product indicated that it 
largely originated from a locus downstream of GALNT3, a gene transcribed with the same 
kinetic as HERVH env62 in the presence of dieldrin (Appendix Fig S4C and D). ERK 
inhibitors U0126 and PD98059 caused strong inhibition of transcription of this HERV 
(Fig 4D–F and Appendix Fig S4E–G). In contrast H89, an inhibitor of PKA and MSK1 
inhibited the transcription of several AP1 genes, but had no effect on the HERV. Wortmannin 
very efficiently inhibited the HERV, documenting the implication of the PI3K pathway. Yet, 
the Akt inhibitor, efficient on the AP1 genes, had no effect on the HERV. To investigate this 
further, we followed up on the fact that dieldrin but not PMA caused phosphorylation of Akt 
at T308 (Fig 4B), a residue modified by PDK1 (Manning & Toker, 2017). BX795, an 
inhibitor PDK1, resulted in repression of the HERV, without affecting any of the other genes 
we tested. As BX795 also targets TBK1 and IKBKE, it is difficult to draw definitive 
conclusions on the pathway at play, but this molecule may provide a potential therapeutic lead 
in diseases associated with increased HERV expression.  
 
 
 Figure 4.Dieldrin activates multiple signal transduction pathways  
A. Schematic of the signal transduction pathways under scrutiny. Used inhibitors are indicated in bold font. 
B. A human phospho‐kinase antibody array was probed with extracts from Jurkat cells treated with either DMSO, dieldrin, or PMA for 
30 min as indicated. The array processed as a Western blot and revealed by ECL. Histogram shows selected antibodies. Values shown 
are means ± SEM from two measures. The full experiment is shown in Appendix Fig S4A and B. 
C. Jurkat cells were treated with either DMSO (vehicle), dieldrin or PMA for the indicated times. Cell extracts were resolved by 
PAGE, and Western blotting was carried out with the indicated antibodies. Nearest size marker is indicated to the right (kDa). 
D–G. Jurkat cells were cultured in the absence or in the presence of the indicated small molecule inhibitors for 1 h then exposed to 
100 μM dieldrin for 30 min. Abundance of mRNA for the indicated genes or HERVs was assessed by RT–qPCR. Data shown are 
means ± SEM from four independent experiments. Significance (P‐value) was estimated using the two‐sided Student's t‐test 
appropriate for small sample numbers. ***P‐value < 0.001, **0.001 < P‐value < 0.01, *0.01 < P‐value < 0.05. 
H. Jurkat cells treated as in (C) were subject to fractionation as indicated in the Materials and Methods section to distinguish a fraction 
with mostly RNAPII S2p (F1), one with mostly histone H3 (F3), and one with both RNAPII S2p and histone H3 (P). Fractions were 
resolved by PAGE, and Western blots were carried out with the indicated antibodies. 
 
Surprisingly, the calcineurin inhibitor FK506 did not affect transcription of HERVH env62 in 
the presence of dieldrin, while suppressing that of TNFα (Fig 4D–F). Therefore, we 
envisioned the implication of peptidylarginine deiminases (PADIs) that are highly dependent 
on intracellular Ca2+ concentrations (Arita et al, 2006), and shown to positively regulate 
several HERVs (Sharma et al, 2012). The PADI inhibitor Cl‐amidine caused a twofold 
reduction in the effect of dieldrin on HERVH env62, while not affecting expression of TNFα 
(Fig 4G). To further document an implication of PADI enzymes in the response to dieldrin, 
we used a previously described cell fractionation protocol (Reyes et al, 1997), involving 
isolation of a very soluble fraction, rich in RNAPII and poor in chromatin (as determined by 
histone H3 content—Fig 4H Fraction F1), a fraction rich in chromatin but containing no 
RNAPII (F3, regarded as containing inactive chromatin), and a pellet containing both 
chromatin and RNAPII (P, regarded as transcribed chromatin). We then examined in these 
fractions the distribution of PADI2, the only PADI enzyme detected in unstimulated and 
dieldrin‐stimulated Jurkat cells. Western blots revealed an increased accumulation of this 
enzyme in transcribed chromatin in cells exposed to dieldrin (Fig 4H PADI2, compare lanes 4 
and 8).  
Altogether, these experiments suggest that the specificity of dieldrin resides in its ability to 
simultaneously activate several pathways, including MAPK, PI3K, and calcium‐dependent 
pathways. Inhibition of any of the three pathways resulted in the loss of HERVH env62 
transcription, suggesting that the cumulative effect of these pathways is required. Possibly, the 
atypical routes including PKC‐uncoupled activation of ERK and a likely activation of PDK1 
downstream of PI3K may also play a role. Importantly, our data also suggest that the effect of 
calcium on both the HERVs and the AP1 genes is mediated by PADI enzymes rather than 
calcineurin and NFAT. This is consistent with our earlier observations showing that 
citrullination of histone H3 at arginine 8 by these enzymes relieves repression by H3K9me3, a 
modification frequently detected at repressed HERVs and at inactive enhancers (Sharma et al, 
2012; Zhu et al, 2012).  
Enhancer activity of HERV‐containing regulatory regions in patients with MS 
Our observations above indicated that HERV transcription in dieldrin‐treated Jurkat cells is at 
least in part the consequence of the activation of enhancers harboring HERV sequences and 
participating in the immune response. To extend this observation to a disease associated with 
HERV transcription and chronic activation of the immune system, we examined existing 
RNA‐seq data from patients with multiple sclerosis (Cao et al, 2015). In this report, 
transcriptomes of sorted myelin‐reactive and non‐myelin‐reactive CCR6+ CD4+ memory T 
cells (respectively referred to as myelin+ and myelin−) were compared between MS patients 
and healthy controls (Fig 5A). Manual examination of these data indicated that multiple 
HERV‐derived sequences annotated as active enhancers in several hematopoietic tissues were 
transcribed abundantly only in the myelin+ T cells from patients with MS (see example in 
Appendix Fig S5A). We next wished to quantify the phenomenon. As the data were not 
stranded, we relied on non‐exonic annotated CAGE peaks to approach putative regulatory 
regions (CAGE regions defined as a 1‐kb interval framing a CAGE peak—Table EV3). 
Overlap between RepeatMasker LTRs and CAGE regions upregulated (P < 0.05) in patient 
with MS (as evaluated by the Jaccard index) was eightfold lower than that of randomly 
selected CAGE regions, indicating that patients with MS maintain a counter‐selection of 
HERV sequences within regulatory regions activated by the disease. Yet, the LTR to CAGE 
similarity index increased at least threefold in the myelin+ T cells, indicating an increased 
usage of LTRs as cis‐regulatory elements in these cells (Fig 5B).  
 
Figure 5.HERV transcripts originate from activated enhancers  
A. Schematic of the experiment. 
B. Comparison of RepeatMasker regions annotated “LTR” or “SINE”, “LINE”, or “SVA” with upregulated CAGE regions (P < 0.05) 
as defined in the text based on the Jaccard similarity index. The graph also provides the average and the standard deviation (error bars) 
of Jaccard indexes calculated for 1,000 series of randomly selected CAGE regions. 
C. Genes activated in myelin+ patient T cells as compared to myelin+ T cells from healthy controls and annotated in GeneHancer as 
interacting with a regulatory element containing an LTR sequence and activated twofold or more (P < 0.05) in myelin+ patient T cells 
as compared to myelin+ T cells from healthy controls: Histogram shows the log2 of fold change in read counts within the indicated 
genes. Error bar corresponds to the log2 fold change standard error as reported by DESeq2. 
D–F. Screen captures from UCSC genome browser showing regulatory elements containing HERV‐derived sequences with 
transcription correlating with that of a nearby gene annotated as linked in the GeneHancer database. 
As a control, we also examined the similarity of the CAGE regions with SINEs and LINEs, 
two other families of repeats. SINEs were not counter‐selected inside the regulatory regions 
activated in patients with MS, and there was no enrichment in SINE‐containing regulatory 
regions in the myelin+ T cells when compared to the myelin− cells. For the LINEs, we 
observed some counter‐selection within regulatory regions activated in patients with MS 
(−58% for the myelin− cells) and there was a moderate (28%) increase in usage of these 
repeats in the myelin+ cells. These observations suggest that MS has a greater effect on 
regulatory elements containing HERV sequences than on those containing other types of 
repeats.  
To document that transcription of regulatory regions harboring HERV‐derived sequences 
actually reflected enhancer activity relevant for MS, we next crossed the list of RepeatMasker 
LTRs with GeneHancer Regulatory Elements for which target genes have been identified by 
chromosome conformation capture techniques (Fishilevich et al, 2017). This allowed us to 
identify a series of genes that (i) were significantly activated in myelin+ cells from patients 
with MS as compared to myelin+ cells from healthy controls and (ii) were linked to a HERV‐
containing enhancer showing at least twofold increased transcription (P < 0.05) in patients 
with MS compared to healthy controls (Fig 5C and Table EV3). Among these, we particularly 
noted activated transcription of a HERV sequence upstream of CCL20, the gene encoding the 
ligand for CCR6. Seemingly, this HERV was the only enhancer‐like activity in the 
neighborhood of CCL20, activated only in the myelin‐reactive patient cells (Fig 5D). An 
example of an intragenic enhancer is shown in Fig 5E. Finally, we noted that the isoform of 
IL1R2 expressed exclusively in myelin‐positive patient cells used a HERV sequence as a 
promoter (Fig 5F).  
Altogether, these observations show that in patients with MS, activation of HERV‐driven 
enhancers and promoters can be a source of HERV transcripts. Furthermore, the observation 
brings strong evidence for an implication of chronically active HERV‐driven enhancers in the 
transcriptional regulation of disease‐associated genes. 
Discussion 
Our objective in this study was to investigate some of the transcriptional aspects behind the 
activity of endogenous retroviral sequences. Our initial hypothesis was that HERV‐derived 
sequences located within or in the vicinity of promoters and enhancers might be transcribed as 
uaRNAs and eRNAs. Examination of the average position of enhancers and promoters 
relative to HERV‐derived sequences revealed that the periphery of regulatory regions is in 
general depleted of retroviral sequences and located at the bottom of a HERV valley. We 
interpret this depletion as a safeguard against serendipitous transcription of HERVs when the 
regulatory element becomes active. This stands out as a remarkable case of shaping of the 
genome sequence by constaints of transcription. 
Our approach also revealed that, with the exception of some embryonic stem cell lines, all 
tissues counter‐select HERV sequences inside their regulatory elements. In other words, any 
randomly selected sequence is more likely to be a promoter or an enhancer than is a HERV‐
derived sequence. When compared to a related analysis based on ENCODE DNase I 
accessibility data rather than chromatin states (Jacques et al, 2013), our analysis confirms the 
cell type‐specific activation of enhancers containing HERV sequences, but it also suggests a 
less widespread usage of HERV sequences inside regulatory elements. Chromatin states as 
calculated by the Epigenomic Roadmap consortium combine data on DNA methylation, 
histone modifications, and chromatin accessibility, and are therefore likely to provide more 
accurate boundaries of regulatory regions than would nuclease‐accessibility assays. This may 
possibly explain some of the differences between our and earlier studies.  
The counter‐selection of HERV sequences inside regulatory sequences is strongest in 
pancreatic islets, in several brain tissues, and in the gastrointestinal tract. Likewise, an earlier 
study has reported that transposons are not an abundant source of enhancers in the 
mammalian neocortex (Emera et al, 2016). We speculate that keeping HERV sequences silent 
in brain may be of particular importance because of the several neurological diseases 
associated with HERV expression in that tissue, including multiple sclerosis, amyotrophic 
lateral sclerosis, and chronic inflammatory demyelinating polyradiculoneuropathy (Küry et al, 
2018). We note also that the low usage of HERVs in pancreatic islets is yet another similarity 
between this tissue and brain tissues, which in numerous studies have been reported to share 
transcriptional programs (Arntfield & van der Kooy, 2011).  
At the other end of the spectrum, stem cells evade the negative selection of HERVs inside 
their regulatory regions. This is compatible with studies reporting the influence of endogenous 
retrovirus‐driven transcription on the maintenance of pluripotency (Wang et al, 2014; Hackett 
et al, 2017). In that context, we note that GO term analysis of genes located in the vicinity of 
HERV‐based regulatory elements suggests a role in cellular defense. Possibly, defense genes 
may be more exposed to viral integration because they are active during acute phases of 
infection. We note also that several HERV‐derived sequences located in the neighborhood 
cytokine genes were annotated as enhancers only in embryonic stem cells (Appendix Figs 
S1M and S3A). This may suggest that innate immunity of embryonic stem cells, which by 
many aspects is different from that of differentiated cells (D'Angelo et al, 2017), relies more 
than other tissues on HERV‐driven transcription.  
While T cells score relatively low in the usage of HERV sequences inside enhancers, they 
seem to be amenable to a limited level of HERV transcription. In the present study, we 
reached this effect by treating the cells with the pesticide dieldrin that induces a strong and, by 
several aspects, atypical T‐cell activation. In particular, the effect of dieldrin stands out from 
classical T‐cell activation by the amplitude of the activation and the number of genes that this 
pesticide induces. The MAPK, PI3K, and calcium‐dependent pathways that get induced are 
standard for T‐cell activation, but there seem to be divergences in the routes taken by these 
pathways in the presence of dieldrin. For example, we observe that activation of ERK in the 
MAPK pathway does not occur through activation of PKC and that NF‐kB does not seem to 
be a major player downstream of the pathway. 
Monitoring the activity of HERV Env62 showed that inhibition of just one of three induced 
pathways interfered with expression of the viral sequence in the presence of dieldrin. Dieldrin 
also caused a re‐localization of PADI2 to chromatin where we have previously shown that 
peptidyl arginine deiminase activity interferes with H3 lysine 9 trimethyl (H3K9me3)‐
mediated silencing and thereby favors transcription of HERV‐derived sequences (Sharma 
et al, 2012). The H3K9me3 histone mark is also involved in regulating enhancer activity (Zhu 
et al, 2012). It is therefore possible that PADI activity, beyond its effect on HERV 
transcription, may allow unlocking of enhancers from earlier stages of cell differentiation and 
thereby increase the range of regulatory regions available for activation of defense genes in 
cells exposed to stress. This scenario is compatible with dieldrin‐treated Jurkat cells relying 
on more embryonic and HERV‐enriched enhancers to confront the stress engendered by the 
pesticide. An activation of dormant enhancers together with induction of multiple signal 
transduction pathways is also consistent with earlier studies indicating that transcription of 
HERV‐derived sequences is the consequence of both de‐repression and activation (Gerdes 
et al, 2016), possibly with the MAPK and the PI3K pathways providing the transcription 
factors for the activation of enhancers de‐repressed by PADI or other H3K9me3‐neutralizing 
activities.  
In the Jurkat T cells exposed to dieldrin, the time window for transcription of the HERV 
sequences we monitored by RT–qPCR was very short and, in the RNA‐seq data, transcription 
of HERV‐derived sequences was difficult to correlate with activation of nearby genes. 
Possibly, the duration of the exposure to dieldrin (30 min) may have been too short to allow 
detectable activation of the target genes of these putative enhancers. Alternatively, 
transcription of HERV‐driven enhancers may play a more general role in early phases of 
chromatin reprogramming and nuclear reorganization associated with T‐cell activation 
(Robson et al, 2017).  
While the kinetic of the HERV transcription in the dieldrin‐treated Jurkat cells is likely to 
reflect the behavior of these sequences in healthy T cells, the data from patients with MS 
provided us with an opportunity to examine the viral sequences in the context of a chronic 
disease‐associated condition. Re‐analysis of this high‐quality data showed that MS does not 
result in the loss of the counter‐selection of enhancers containing HERV‐derived sequences. 
Yet, in the myelin‐autoreactive CD4+ T cells, this counter‐selection is reduced. In these cells, 
we could also observe an increased activity of a series of enhancers containing HERVs, many 
of which were located in the neighborhood of activated immune genes. This is a strong 
argument in favor of the contribution of HERV‐driven transcriptional activity in the immune 
mechanisms of MS pathogenesis. It also defines enhancer activity as a very likely source of 
HERV transcripts in patients with MS.  
Materials and Methods 
Antibodies and chemicals 
Antibodies used for Western blot: anti‐Phospho‐PKC (Cell Signaling 9371T), anti‐REL A 
(Cell Signaling 3033T), anti‐NFAT‐1 (BD Transduction Laboratories 610702), anti‐BRG1 
(Euromedex 2E12), anti‐RNA Pol 2 pS2 (Abcam 5095), anti‐H3 (Abcam 1791), anti‐PADI2 
(Abcam 56928), and anti‐BRG1 (Euromedex 2E12). Each antibody was profiled by the 
vendor as appropriate for Western blots. Chemicals used in this study: Dieldrin and PMA 
were purchased from SIGMA (Ref 291218, and P1585, respectively). The inhibitors used for 
the pathways determination: wortmannin (Sigma W3144), BX795 (Sigma SML0694), Akt1/2 
kinase inhibitor (Sigma A6730), H89 (Sigma B1427), U0126 (EMD Millipore 19147), FK506 
(Enzo Life Sciences ALX 380 008), and PD98059 (Selleckchem S1177). Cl‐amidine was 
purchased from EMD Millipore (reference 506282). 
Cell culture 
Jurkat E6‐1 cells purchased from ATCC were cultured in RPMI‐1640 with 10% 
decomplemented fetal bovine serum (FBS) and 100 U ml−1 penicillin–streptomycin at 37°C in 
a 5% CO2 incubator. Cells were treated with phorbol myristate acetate (PMA) or dieldrin at 
100 μM for the indicated times, with wortmannin (10 mM), BX795 (6 μM), Akt1/2 kinase 
inhibitor (40 μM), H89 (40 μM), U0126 (12 μM), FK506 (100 nM), and PD98059 (25 μM) 
for 1 h and with 200 μM Cl‐amidine for exactly 16 h in complete cell culture medium.  
mRNA, protein quantification, and cell fractionation 
Total RNA from Jurkat cells was extracted with a phenol–chloroform‐based method and 
quantified with an ND‐1000 (Nanodrop). After DNase treatment (Roche), reverse 
transcription was performed using SuperScript III (Invitrogen) and random hexanucleotides 
according to the manufacturer's instructions. Complementary DNAs were quantified by RT–
qPCR (Mx3005P, Stratagene) using SYBR Green PCR master mix (Applied Biosystems). 
PCR primers are listed in Appendix Table S1. Data are shown relative to RPLP0 considered 
invariant. Total proteins were separated by electrophoresis on 4–12% gradient PAGE gels 
(Bio‐Rad, #345–0124) and transferred on nitrocellulose membrane (Bio‐Rad, #1620115) for 
Western blot with indicated antibodies. Cell fractionation was carried out as previously 
described (Reyes et al, 1997).  
High‐throughput RNA sequencing and bioinformatics 
Stranded libraries of cDNA were prepared by random priming followed by either enrichment 
in poly(dA) with an oligo(dT) resin or depletion from ribosomal RNA. A minimum of 30‐Gb 
sequencing was obtained for each sample with reads of 150 bases. All poly(dA)‐enriched 
libraries were sequenced on a same flow cell. Reads were aligned with STAR 2.5.0a (Dobin 
et al, 2013) on human genome version Hg19 primary assembly without patches, allowing 
only single alignments. Differential expression analysis on poly(dA)‐enriched libraries was 
performed with DESeq2 1.14.1 (Love et al, 2014), and raw counts were corrected with a 
TMM normalization. Divergent transcription sites were extracted from the previous 
alignments by identifying region in between groups of reads mapping on opposite strands 
separated by < 500 bp, developing a python module (available at 
https://github.com/khourhin/divtrans_azebi_2019) wrapping bedtools 2.27.1 and samtools 
1.9. Reads inside HERV sequences and chromatin states were quantified with featureCount 
1.6.0 from the Subread package (Liao et al, 2014). Identification of genes in the neighborhood 
of HERVs was carried out with GREAT (McLean et al, 2010). Jaccard indexes were 
calculated with bedtools 2.27.1, while profiles were generated with deepTools3.0.1. Panels 
with chromatin states were screen captures from NIH Roadmap Epigenomics Mapping 
Consortium web site 
(https://egg2.wustl.edu/roadmap/web_portal/chr_state_learning.html#core_15state).  
Statistics 
GO term analysis with GREAT shows −log10 of the binomial P‐value. The binomial test is 
potentially biased by a large number of genomic regions being associated with a small set of 
genes. We therefore ensured that for each indicated pathway, the hypergeometric test also 
indicated significant enrichment. In the transcriptomic analysis, significance was estimated 
based on the P‐value adjusted according to the Benjamini and Hochberg correction. Two‐
sided Student's t‐test was used when sample numbers were small.  
Human subjects 
The CD4+ T‐cell data from patient with MS have been deposited under the BioProject 
accession no. GSE66763. The original publication stated that peripheral blood was drawn 
from healthy individuals and patients with MS after informed consent and approval by the 
Institutional Review Board at Yale University School of Medicine. All patients had relapsing‐
remitting MS and were aged 42 ± 12 years. All patients were immunotherapeutic‐naïve 
(untreated) or had not received treatment for at least 12 months. Healthy donors were age‐ and 
sex‐matched with the MS patients, with no history of autoimmune disease or malignancies 
and no acute or chronic infections (Cao et al, 2015).  
Data availability 
All RNA‐seq data were deposited on GEO with the record number GSE111167.  
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Appendix Figure S1: Genome-wide localization of HERVs relative to promoters and enhancers
(A) Comparison of regions annotated “LTR” in RepeatMasker with the regions annotated TssA, TssAFlnk, Enh, EnhG, TssBiv, or
EnhBiv in the 15 core marks model of the Epigenomic Roadmap consortium (referred to as PEs for Promoters and Enhancers).
For each tissue, the Jaccard index comparing PEs to LTRs is divided by the average Jaccard index (1000 iterations) obtained
when comparing PEs to randomly selected genomic locations (of the same sizes as the LTRs).
(B) Regions annotated “LTR” in RepeatMasker compared with the indicated regions. For each set of regions, the Jaccard index
comparing PEs or CREs to LTRs is divided by the average Jaccard index (1000 iterations) obtained when comparing the PEs or
CREs to randomly selected genomic locations (of the same sizes as the LTRs). Tissue-specific PEs were selected as PEs present
in the indicated tissue and not overlapping with PEs from other tissues. Ubiquitous PEs were selected as PEs overlapping with
a PE in all tissues. “H1 BMP4 Derived Mesoderm Cultured Cells” and “Fetal Brain Female” provide min. and max. similarity of
tissue-specific PEs with LTRs.
(C-F) Profile reporting the position of regions annotated “LTR” in RepeatMasker relative to PEs from the indicated tissues. Each
panel reports profiles from related tissues as indicated.
(G-I) Profile reporting the position of regions annotated “ERVL”, “ERV1”, or “ERVK” in RepeatMasker relative to PEs from the
indicated tissues.
(J) Comparison regions annotated “ERVL”, “ERV1”, or “ERVK” in RepeatMasker with CAGE peaks from the FANTOM5 consortium.
For each HERV clade, the Jaccard index comparing LTRs to CAGE peaks is divided by the average Jaccard index (1000 iterations)
obtained when comparing CAGE peaks to randomly selected genomic locations (of the same sizes as each of the HERV clades).
(K-L) Biological process GO terms associated with genes located 100 kb or less from a region annotated “ERVL” or “ERV1” in
RepeatMasker and overlapping with a CAGE peak.
(M) Position of the LTR upstream of IL6 relative to functional annotations in the 127 tissues of the Epigenomic Roadmap
consortium. Color code: red, active TSS, orange red, flanking active TSS, lime green, transcription at gene 5' and 3', green,
strong transcription, dark green, weak transcription, green yellow, genic enhancers, yellow, enhancers, medium aquamarine,
ZNF genes & repeats, pale turquoise, heterochromatin, Indian red, bivalent/poised TSS, darksalmon, flanking bivalent TSS/Enh,
dark khaki, bivalent enhancer, silver, repressed polycomb, Gainesboro, weak repressed polycomb, white, quiescent/low.
(N) For each of the 127 tissues mapped by Epigenomic Roadmap consortium, regions annotated “LTR” in RepeatMasker and
overlapping with a CAGE peak from the FANTOM5 consortium data (CAGE-LTRs) are compared with PEs. For each tissue, the
Jaccard index comparing PEs to CAGE-LTRs is divided by the average Jaccard index (1000 iterations) obtained when comparing
PEs to randomly selected genomic locations (of the same sizes as the CAGE-LTRs).
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Appendix Figure S2: Dieldrin is a strong T cell activator causing transcription of several HERVs
(A) Description and references linking HERVs to MS.
(B) To estimate the number of loci amplified by the primers, digital droplet PCR was carried out on Jurkat cell DNA, using DNA from a haploid
cell line as a reference.
(C) Impact of dieldrin on cell viability at the indicated times.
(D) Jurkat T cells were treated with either DMSO (vehicle) or with 100µM of either Dieldrin or PMA for the indicated times. Abundance of
mRNA for the indicated genes was assessed by RT-qPCR. Data shown are means +/- SEM from three independent experiments.
Significance (p-value) was estimated using the two-sided student t test.
(E, F) MA-plot recapitulating changes in gene expression in the presence of PMA or dieldrin as indicated. Every dot represents a gene. Red
color signals significant change (FDR<0.05).
(G, H) Jurkat cells were treated for indicated times with either DMSO (vehicle) or 100µM of either dieldrin or PMA. Abundance of mRNA for
the indicated genes was assessed by RT-qPCR. Data shown are means +/- SEM from three independent experiments. Significance (p-value)
was estimated using the two-sided student t test.
***: p-value<0.001, **: 0.001<p-value<0.01, *: 0.01<p-value<0.05.
ARefSeq
DMSO
Dieldrin
Coverage
Oriented reads
Coverage
Oriented reads
Summarized visualization of all 127 epigenomes using epilogos (https://epigenomegateway.wustl.edu/browser/?genome=hg19&datahub=http://egg2.wustl.edu/roadmap
/data/byFileType/chromhmmSegmentations/ChmmModels/epilogos/observed/qcat.json)
Emission, transition probabilities and enrichment of states relative to various genomic and functional annotations (http://egg2.wustl.edu/roadmap/data/byFileType
/chromhmmSegmentations/ChmmModels/coreMarks/jointModel/final/annotationEnrichment_RoadmapEp_coreMarks_15State.png)
MNEMONICS BED FILES ( [Epigenome_id]_15_coreMarks_mnemonics.bed.gz files )
Tab delimited 4 columns
chromosome, start (0-based), stop (1-based), state_label_mnemonic for that region
ARCHIVE (http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/coreMarks/jointModel/final/all.mnemonics.bedFiles.tgz) of all mnemonics.bed files
BROWSER FRIENDLY FILES ([Epigenome_id]_15_coreMarks_dense.bb)
The dense BIGBED files will allow you to view each epigenome as a single track with regions labeled with state mnemonics and representative colors. You can stream these to UCSC
Genome Browser or IGV
ARCHIVE (http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/coreMarks/jointModel/final/all.dense.bb.tgz ) of all the dense BIGBED files
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MNEMONICS BED FILES ( [Epigenome_id]_15_coreMarks_mnemonics.bed.gz files )
Tab delimited 4 columns
chromosome, start (0-based), stop (1-based), state_label_mnemonic for that region
ARCHIVE (http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/coreMarks/jointModel/final/all.mnemonics.bedFiles.tgz) of all mnemonics.bed files
BROWSER FRIENDLY FILES ([Epigenome_id]_15_coreMarks_dense.bb)
The dense BIGBED files will allow you to view each epigenome as a single track with regions labeled with state mnemonics and representative colors. You can stream these to UCSC
Genome Browser or IGV
ARCHIVE (http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/coreMarks/jointModel/final/all.dense.bb.tgz ) of all the dense BIGBED files
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MNEMONICS BED FILES ( [Epigenome_id]_15_coreMarks_mnemonics.bed.gz files )
Tab delimited 4 columns
chromosome, start (0-based), stop (1-based), state_label_mnemonic for that region
ARCHIVE (http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/coreMarks/jointModel/final/all.mnemonics.bedFiles.tgz) of all mnemonics.bed files
BROWSER FRIENDLY FILES ([Epigenome_id]_15_coreMarks_dense.bb)
The dense BIGBED files will allow you to view each epigenome as a single track with regions labeled with state mnemonics and representative colors. You can stream these to UCSC
Genome Browser or IGV
ARCHIVE (http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/coreMarks/jointModel/final/all.dense.bb.tgz ) of all the dense BIGBED files
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Appendix Figure S3: Dieldrin causes transcription of HERV-containing PEs atypical for activated T cells
(A-C) Position of LTRs described in the result section relative to functional annotations in the 127 tissues of the Epigenomic Roadmap
consortium. Color code as in Appendix Figure S1. Arrow heads indicate remarkable PEs (read arrow indicates PEs active in embryonic or
cancer cells; black arrows indicate PEs active in T cells).
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Appendix Figure S4: Dieldrin activates multiple signal transduction pathways.
(A) A human phospho-kinase antibody array was probed with extracts from Jurkat cells treated with either DMSO, dieldrin, or
PMA for 30 min as indicated. On the array, each antibody is spotted twice. The array was processed as a western and revealed
by ECL. Spots were quantified using Fiji; Values shown are means +/- SEM from measures of the two spots for each antibody.
Arrow points at AKT S473 phosphorylation.
(B) Spots in the array quantified in A are distributed as indicated by the provider of the array
(https://resources.rndsystems.com/pdfs/datasheets/ary003b.pdf).
(C) Screen capture from the UCSC genome browser locating the HERVH env62 PCR product downstream of the GALNT3 gene. The
link annotated in the GeneHancer data and connecting the regulatory region to the promoter of the GALNT3 gene is also
indicated.
(D) Jurkat cells were exposed to 100μM dieldrin for the indicated times. Abundance of GALNT3 mRNA was assessed by RT-qPCR.
Data shown are means +/- SEM from three independent experiments. Significance (p-value) was estimated using the two-sided
student t test.
(E-G) Jurkat cells were cultured in the absence or in the presence of the MEK inhibitor PD98059 for 1h then exposed to 100μM
dieldrin for 30 min. Abundance of mRNA for the indicated genes or HERVs was assessed by RT-qPCR. Data shown are means +/-
SEM from three independent experiments. Significance (p-value) was estimated using the two-sided student t test.
***: p-value<0.001, **: 0.001<p-value<0.01.
RefSeq
MS myelin+
RM LTRs
Oriented CAGE
MS myelin-
Cont myelin+
Cont myelin-
A
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MNEMONICS BED FILES ( [Epigenome_id]_15_coreMarks_mnemonics.bed.gz files )
Tab delimited 4 columns
chromosome, start (0-based), stop (1-based), state_label_mnemonic for that region
ARCHIVE (http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/coreMarks/jointModel/final/all.mnemonics.bedFiles.tgz) of all mnemonics.bed files
BROWSER FRIENDLY FILES ([Epigenome_id]_15_coreMarks_dense.bb)
The dense BIGBED files will allow you to view each epigenome as a single track with regions labeled with state mnemonics and representative colors. You can stream these to UCSC
Genome Browser or IGV
ARCHIVE (http://egg2.wustl.edu/roadmap/data/byFileType/chromhmmSegmentations/ChmmModels/coreMarks/jointModel/final/all.dense.bb.tgz ) of all the dense BIGBED files
[Epigenome_id]_15_coreMarks_dense.bed.gz (Same as above except in text format)
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Target gene log2FoldChange pvalue GeneHancer item Fold Change T test Overlapping LTRs
FASLG 10,41 3,5756E-21GH01J172637 6543,00 0,044MLT1B
CCL20 3,87 3,231E-15GH02J227805 135,95 0,004LTR16A
ZNF267 5,93 2,8757E-11GH16J031879 379,20 0,019MER21B,MLT1H1
AIM2 6,60 4,7344E-06GH01J159067 55,56 0,017ERV3-16A3_LTR,LTR81C,MLT1A0
KLHL6 4,08 6,9746E-06GH03J183552 35,73 0,045LTR85c,MER21A,MER51B,MLT1L,PABL_A
PRNP 5,08 9,9981E-06GH20J004664 230,00 0,028LTR70
CD44 3,02 1,4447E-05GH11J035076 982,00 0,028MLT1H2,MSTB
TRAF1 3,11 1,5481E-05GH09J120916 74,75 0,058LTR16E1,LTR2C
RNF19A 3,42 4,5298E-05GH08J100296 18,40 0,019ERVL-E-int
LRRC8C 4,16 7,387E-05GH01J089755 577,00 0,016LTR1B,LTR1C,LTR8,MLT1A
CD96 2,51 0,00124374GH03J111607 34,59 0,027MLT1B
CMAHP 3,45 0,01209303GH06J025130 12,08 0,019MLT1I
NABP1 2,55 0,01707621GH02J191695 10,83 0,047MLT1F1
NEDD9 2,12 0,02569855GH06J011349 45,53 0,034MLT2B5
SYS1 1,85 0,03610297GH20J044965 3,26 0,009MER39
JARID2 2,13 0,03816523GH06J015322 2902,00 0,021MLT1B
DUSP28 2,68 0,04287648GH02J240564 55,35 0,007MER4-int
VHL 2,04 0,0482829GH03J010188 82,89 0,015MLT1D,MLT1J2
CDK17 2,36 0,04837823GH12J096419 10,62 0,014MLT1B,MLT1D
B
Figure S5
Appendix Figure S5: HERV transcripts originate from activated enhancers.
(A) Top panel: screen captures from IGV showing a HERV overlapping with a region annotated as an enhancer in several tissues but
showing increased transcription only in the data from myelin+ patient T cells. Bottom panel: position of the LTR downstream
relative to functional annotations in the 127 tissues of the Epigenomic Roadmap consortium. Color code as in Appendix Figure S1.
(B) Table listing the genes described in Figure 5C and indicating the connected GeneHancer item, its fold activation in myelin+ patient T
cells as compared to myelin+ T cells from healthy controls, and the annotation of the overlapping HERV-derived sequence from
RepeatMasker.
Primer name Forward (5'-3') Revers (5'-3')
HERV-H/env62 (AJ289709.1) TGGCCGCTCCTTTGTGTATCTCTT ACAGGGCAAGTGTCTTCCTAAGCA 
HERV-H/env59 (AJ289711.1) TTTATCAGTCCTCCAGGCCCAAGT AAGAATTGGGAGGACCCAGGACAT 
HERV-H/env60 (AJ289710.2) AGGCCTTGACTTACTCACTGCTGA TTGGAAGGACCCAGGACATCCAAT 
HERV-H/pol62 CCTTCAGCATTTATTCTCCAAAGG GAAGAATTATGCCGAGGTAGGGTAA
HERV-K18/LTR (AF333072) GGCGGTGCAAGATGTGCTTTGTTA ACCAGCGTTCAGCATATGGAGGAT
HERV-K102/env TGCCAAACCTGAGGAAGAAGGGAT TGCAGGCATTAAACATCCTGGTGC
HERV-W/env TCAGCTTAACTCCCTAGCAGCAGT TTCGAAGCTCCTCTGCTCTACGTT
RPLP0 AGGTGTTCGACAATGGCAGCAT TGCAGACAGACACTGGCAACAT
TGFbeta1 ATGAACCGGCCTTTCCTGCTTC AAGCAATAGTTGGTGTCCAGGGCT 
TNFalpha GCCCATGTTGTAGCAAACCCTCAA AGTAGATGAGGTACAGGCCCTCTGAT 
IL8 CCACACTGCGCCAACACAGAAATTA AAACTTCTCCACAACCCTCTGCAC
c-FOS GAGAATCCGAAGGGAAAGGAATAA TTCTCATCTTCTAGTTGGTCTGTC
FOSB CTCGGCCTAGGTCACGTT GCCAGAGTTTCTAGAAGCAGTTT
c-JUN ATCAAGGCGGAGAGGAAGCG TGAGCATGTTGGCCGTGGAC
IL2 CCAAACTCACCAGGATGCTCACAT AGCACTTCCTCCAGAGGTTTGAGT
GALNT3 CTCTATGTCTGGATGTTGGAGAAA GAGCAGAGTATTCAAAGTACTGGT
CYP1A1 TCTTCCTTCGTCCCCTTCAC TGGTTGATCTGCCACTGGTT 
CYP1B1 GCCTGTCACTATTCCTCATGCCA ATCAAAGTTCTCCGGGTTAGGCCA
NQO1 TCCCCCTGCAGTGGTTTGGAGT ACTGCCTTCTTACTCCGGAAGGGT 
GCLC GAACAATGTCCGAGTTCAATACAG GCTTGTTTATTGCTTCATCTGGAA 
GCLM TCAACCCAGATTTGGTCAGGGAGT TCCAGCTGTGCAACTCCAAGGA
SLC6A12 ATAGTGGCCCTGTATTTTATCCTG ATCCCAGAAGTTGTAAAAGCAGTA
SLC5A3 ATAGTGGCCCTGTATTTTATCCTG ATCCCAGAAGTTGTAAAAGCAGTA
AKR1B1 AGAACGCATTGCTGAGAACTTTAAGGTC GTAATC CTTGTGGGAGGTACAGCTCAAC 
CDKN1A AGGTGGACCTGGAGACTCTCAG TCCTCTTGGAGAAGATCAGCCG
MDM2 GGAGCAGGCAAATGTGCAATACCA TTCCGAAGCTGGAATCTGTGAGGT
BAX AGGG TTTCATCCAGGATCGAGCAG ATCTTCTTCCAGATGGT GAGCGAG
VEGF CTACCTCCACCATGCCAAGT GCAGTAGCTGCGCTGATAGA
DNAJB9 GTAAAGGACAAAGAGGTAGTGGAA TGATTTTCAAAACGCTTCTTGGAT
MT1E GACCCCAACTGCTCTTGC GCATTTGCACTCTTTGCACTT
MT2A GCGTGCAACCTGTCCCGACTC TGGGATCCATGGCGTGCT
HSP90B1 GACGGATGATGAAGTAGTACAGAG GTGATGCATTTAATCCATCCAACT 
HSPA6 CAAGGTGCGCGTATGCTAC GCTCATTGATGATCCGCAACAC
RPLP0 promoter ACAGAGCGACACTCCGTCTCAAA ACCTGGCGAGCTCAGCAAACTAAA 
FOSB promoter AGAATAAACCCCAACCCCA AACATCTCCCGACTCTTTGC
c-FOS promoter AGCAGTTCCCGTCAATCCC AGGGCTACAGGGAAAGGC
TNFalpha promoter AAACACAGGCCTCAGGACTCAACA ACCAGGTCTGTGGTCTGTTTCCTT
IL8 promoter AAGAAAACTTTCGTCATACTCCG TGGCTTTTTATATCATCACCCTAC
TGFbeta1 promoter ATGGCACCGCTTCTGTCCTTTCTA TAAGCAGCCTCCTGTCACTCAACA
chr11 TGGAATAGTCGTGATTGAGGGA CCAGCAAGTATTTCCTCACCAA
